Villar, Sara http://orcid.org/0000-0002-4761-6692
Chevret, Sylvie
Poire, Xavier http://orcid.org/0000-0003-1897-0227
Joris, Magalie
Chevallier, Patrice http://orcid.org/0000-0003-3142-5581
Bourhis, Jean-Henri
Forcade, Edouard http://orcid.org/0000-0002-8873-2868
Chantepie, Sylvain
Beauvais, David http://orcid.org/0000-0003-1866-828X
Raus, Nicole
Bay, Jacques-Olivier
Loschi, Michael http://orcid.org/0000-0002-4460-5939
Devillier, Raynier http://orcid.org/0000-0002-4045-8310
Duléry, Remy http://orcid.org/0000-0002-5024-1713
Ceballos, Patrice
Rubio, Marie Thérèse
Servais, Sophie
Nguyen, Stephanie
Robin, Marie http://orcid.org/0000-0003-1388-9876
Article History
Received: 30 November 2023
Revised: 5 March 2024
Accepted: 6 March 2024
First Online: 21 March 2024
Competing interests
: The authors declare no competing interests in relationship with the current study. MR: research support by Novartis, MEDAC, NEOVII, ASTEX, ABBVIE. RD: research funding from Ligue contre le Cancer, Arthur Sachs, Monahan Foundation, Servier Foundation, Philippe Foundation, DCP AP-HP, honoraria from Novartis and Takeda, and non-financial support from Kite Pharma/Gilead, all outside the submitted work.